EuroPCR 2018 | SAPIEN 3 in bicuspids

First generation TAVR procedures performed on patients with bicuspid aortic valve stenosis have rendered suboptimal outcomes. In addition, studies on new generation devices, such as the SAPIEN 3, have systematically excluded these patients from their protocols. Therefore, we are missing information about TAVR on bicuspid aortic valve stenosis patients.

This study compared SAPIEN 3 TAVR outcomes in bicuspid vs. tricuspid aortic valve stenosis patients from the real world registry STS / ACC TVT. The registry included 63851 patients, 1792 presenting bicuspid vs. 55023 with tricuspid cases.

 

Patients with bicuspid anatomy resulted younger and with relatively lower risk than the rest. TAVR in this population had a successful rate of 96.6% and a very low complications rate associated to the procedure (less than 1% of annular rupture, need of second valve or conversion to conventional surgery).


Read also: EuroPCR 2018 | Meta-Analyzis on Cerebral Protection Devices during TAVR.


The rate of stroke resulted superior in the group with bicuspid anatomy (2.5% vs 0.9%).

 

Paravalvular leak rate was low and similar in both groups.

 

Conclusion

TAVR with SAPIEN 3 should be considered an alternative in intermediate to high surgical risk patients with bicuspid aortic valve stenosis.

 

Original title: SAPIEN 3 outcomes for bicuspid vs tricuspid aortic valve stenosis: propensity matched results.

Presenter: Raj Makkar.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...